Levi & Korsinsky Reminds Rocket Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - RCKT - Rocket Pharmaceuticals ( NASDAQ:RCKT )
NEW YORK, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ( "Rocket" or the "Company" ) RCKT of a class action securities lawsuit.
DEADLINE ALERT for RCKT, TEM, and DDD: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - 3D Sys ( NYSE:DDD ) , Rocket Pharmaceuticals ( NASDAQ:RCKT )
LOS ANGELES, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action - RCKT - Rocket Pharmaceuticals ( NASDAQ:RCKT )
NEW YORK, Aug. 10, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. RCKT between September 17, 2024 and May 26, 2025, both dates inclusive ( the "Class Period" ) , of the important August 11, ...
RCKT DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in...
New York, New York-- ( Newsfile Corp. - August 9, 2025 ) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. ( NASDAQ: RCKT ) between September 17, 2024 and May 26, 2025, both dates inclusive ( the "Class Period" ) , of the ...
MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Rocket Pharmaceuticals ( NASDAQ:RCKT )
SAN DIEGO, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Robbins Geller Rudman & Dowd LLP announces that the Rocket Pharmaceuticals class action lawsuit - captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 ( D.N.J. ) - seeks to represent purchasers or acquirers of Rocket Pharmaceuticals, Inc.
Rocket ( RCKT ) Q2 Loss Narrows 16%
Rocket Pharmaceuticals ( NASDAQ:RCKT ) , a biotechnology company focused on gene therapies for rare and serious diseases, reported its second quarter 2025 results on August 7, 2025. The most significant news was the clinical hold placed on its lead Danon disease gene therapy program following a ...
Rocket Pharmaceuticals, Inc. ( RCKT ) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial - Hagens Berman - Rocket Pharmaceuticals ( NASDAQ:RCKT )
SAN FRANCISCO, Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- When, on May 27, 2025, Rocket Pharmaceuticals ( NASDAQ:RCKT ) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, ...
Rocket Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 11, 2025 Deadline to file Lead Plaintiff Motion - Rocket Pharmaceuticals ( NASDAQ:RCKT )
Investors can contact the law firm at no cost to learn more about recovering their losses
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - Rocket Pharmaceuticals ( NASDAQ:RCKT )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options
Rocket Pharmaceuticals, Inc. ( RCKT ) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial - Hagens Berman - Rocket Pharmaceuticals ( NASDAQ:RCKT )
SAN FRANCISCO, Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- When, on May 27, 2025, Rocket Pharmaceuticals ( NASDAQ:RCKT ) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, ...
DEADLINE ALERT for VSTS, RCKT, TEM, and DDD: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - 3D Sys ( NYSE:DDD ) , Rocket Pharmaceuticals ( NASDAQ:RCKT )
LOS ANGELES, Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
AUGUST 11 DEADLINE: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law - Rocket Pharmaceuticals ( NASDAQ:RCKT )
SAN DIEGO, Aug. 03, 2025 ( GLOBE NEWSWIRE ) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Rocket Pharmaceuticals class action lawsuit - captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049, and pending in the District of New Jersey - seeks to represent purchasers ...
RCKT IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL FIRM Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action - RCKT - Rocket Pharmaceuticals ( NASDAQ:RCKT )
NEW YORK, Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. RCKT between September 17, 2024 and May 26, 2025, both dates inclusive ( the "Class Period" ) , of the important August 11, ...
RCKT 10-DAY DEADLINE ALERT: FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals ( RCKT ) Stock Plunge and Class Action - Hagens Berman - Rocket Pharmaceuticals ( NASDAQ:RCKT )
SAN FRANCISCO, Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- When, on May 27, 2025, Rocket Pharmaceuticals ( NASDAQ:RCKT ) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, ...
RCKT DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action - RCKT - Rocket Pharmaceuticals ( NASDAQ:RCKT )
NEW YORK, July 31, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. RCKT between September 17, 2024 and May 26, 2025, both dates inclusive ( the "Class Period" ) , of the important August 11, ...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - Rocket Pharmaceuticals ( NASDAQ:RCKT )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options
Rocket Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 11, 2025 Deadline to file Lead Plaintiff Motion. - Rocket Pharmaceuticals ( NASDAQ:RCKT )
Investors can contact the law firm at no cost to learn more about recovering their losses
RCKT LAWSUIT ALERT: Levi & Korsinsky Notifies Rocket Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Rocket Pharmaceuticals ( NASDAQ:RCKT )
NEW YORK, July 28, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ( "Rocket" or the "Company" ) RCKT of a class action securities lawsuit.
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT - Rocket Pharmaceuticals ( NASDAQ:RCKT )
NEW YORK, July 28, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. RCKT between September 17, 2024 and May 26, 2025, both dates inclusive ( the "Class Period" ) , of the important August 11, ...
DEADLINE ALERT: Holzer & Holzer, LLC Reminds Investors of August 11, 2025 Lead Plaintiff Deadline in the Rocket Pharmaceuticals, Inc. ( RCKT ) Class Action - Investors With Significant Losses Encouraged to Contact the Firm - Rocket Pharmaceuticals ( NASDAQ:RCKT )
ATLANTA, July 28, 2025 ( GLOBE NEWSWIRE ) -- A shareholder class action lawsuit has been filed Rocket Pharmaceuticals, Inc. ( "Rocket Pharmaceuticals" or the "Company" ) RCKT. The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to adequately ...
RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law - Rocket Pharmaceuticals ( NASDAQ:RCKT )
SAN DIEGO, July 26, 2025 ( GLOBE NEWSWIRE ) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Rocket Pharmaceuticals class action lawsuit - captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049, and pending in the District of New Jersey - seeks to represent purchasers ...
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT - Rocket Pharmaceuticals ( NASDAQ:RCKT )
NEW YORK, July 25, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. RCKT between September 17, 2024 and May 26, 2025, both dates inclusive ( the "Class Period" ) , of the important August 11, ...
Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours - Rocket Pharmaceuticals ( NASDAQ:RCKT )
BofA cuts Rocket's rating to Neutral, slashing price target from $9 to $4 amid pipeline uncertainty. FDA placed a clinical hold on Rocket's pivotal trial for Danon disease gene therapy in May. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals ( RCKT ) Stock Plunge and Class Action - Hagens Berman - Rocket Pharmaceuticals ( NASDAQ:RCKT )
SAN FRANCISCO, July 23, 2025 ( GLOBE NEWSWIRE ) -- When, on May 27, 2025, Rocket Pharmaceuticals ( NASDAQ:RCKT ) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, ...
ROSEN, A TOP RANKED LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT - Rocket Pharmaceuticals ( NASDAQ:RCKT )
NEW YORK, July 22, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. RCKT between February 27, 2025 and May 26, 2025, both dates inclusive ( the "Class Period" ) , of the important August 11, ...
Investors in Rocket Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT - Rocket Pharmaceuticals ( NASDAQ:RCKT )
NEW YORK, July 22, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ( "Rocket" or the "Company" ) RCKT of a class action securities lawsuit.
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Rocket Pharmaceuticals, Inc. ( RCKT ) Investors - Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - Rocket Pharmaceuticals ( NASDAQ:RCKT )
ATLANTA, July 21, 2025 ( GLOBE NEWSWIRE ) -- A shareholder class action lawsuit has been filed Rocket Pharmaceuticals, Inc. ( "Rocket Pharmaceuticals" or the "Company" ) RCKT. The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to adequately ...
INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - RCKT - Rocket Pharmaceuticals ( NASDAQ:RCKT )
SAN DIEGO, July 21, 2025 ( GLOBE NEWSWIRE ) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - Rocket Pharmaceuticals ( NASDAQ:RCKT )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options
DEADLINE ALERT for VSTS, RCKT, TEM, and DDD: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - 3D Sys ( NYSE:DDD ) , Rocket Pharmaceuticals ( NASDAQ:RCKT )
LOS ANGELES, July 18, 2025 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.
Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT - Rocket Pharmaceuticals ( NASDAQ:RCKT )
NEW YORK, July 17, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ( "Rocket" or the "Company" ) RCKT of a class action securities lawsuit.
FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals ( RCKT ) Stock Plunge and Class Action- Hagens Berman - Rocket Pharmaceuticals ( NASDAQ:RCKT )
SAN FRANCISCO, July 17, 2025 ( GLOBE NEWSWIRE ) -- When, on May 27, 2025, Rocket Pharmaceuticals ( NASDAQ:RCKT ) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, ...
NASDAQ: RCKT INVESTOR ALERT: Berger Montague Advises Rocket Pharmaceuticals ( RCKT ) Investors of August 11, 2025 Deadline - Rocket Pharmaceuticals ( NASDAQ:RCKT )
PHILADELPHIA, July 17, 2025 ( GLOBE NEWSWIRE ) -- Berger Montague PC, a Philadelphia-based law firm focused on investor protection, is investigating claims against Rocket Pharmaceuticals, Inc. RCKT ( "Rocket Pharmaceuticals" or the "Company" ) for potential violations of federal securities laws.
Rocket Pharmaceuticals, Inc. ( RCKT ) Securities Fraud Class Action Lawsuit Pending: Contact Wolf Haldenstein Before August 11, 2025 to Discuss Your Rights - Rocket Pharmaceuticals ( NASDAQ:RCKT )
NEW YORK, July 16, 2025 ( GLOBE NEWSWIRE ) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed on behalf of all investors who purchased or otherwise acquired securities of Rocket Pharmaceuticals, Inc.
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT - Rocket Pharmaceuticals ( NASDAQ:RCKT )
NEW YORK, July 16, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. RCKT between February 27, 2025 and May 26, 2025, both dates inclusive ( the "Class Period" ) , of the important August 11, ...
Lost Money on Rocket Pharmaceuticals, Inc. ( RCKT ) ? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm - Rocket Pharmaceuticals ( NASDAQ:RCKT )
NEW YORK, July 16, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. RCKT. Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff ...
Investors in Rocket Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT - Rocket Pharmaceuticals ( NASDAQ:RCKT )
NEW YORK, July 14, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ( "Rocket" or the "Company" ) RCKT of a class action securities lawsuit.
DEADLINE ALERT for RCKT, DDD, TEM, RDDT: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions - 3D Sys ( NYSE:DDD ) , Rocket Pharmaceuticals ( NASDAQ:RCKT )
BENSALEM, Pa., July 14, 2025 ( GLOBE NEWSWIRE ) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
ROSEN, A TOP-RANKED LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT - Rocket Pharmaceuticals ( NASDAQ:RCKT )
NEW YORK, July 13, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. RCKT between February 27, 2025 and May 26, 2025, both dates inclusive ( the "Class Period" ) , of the important August 11, ...
August 11, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RCKT - Rocket Pharmaceuticals ( NASDAQ:RCKT )
NEW YORK, July 11, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ( "Rocket" or the "Company" ) RCKT of a class action securities lawsuit.
Deadline Alert: Rocket Pharmaceuticals, Inc. ( RCKT ) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - Rocket Pharmaceuticals ( NASDAQ:RCKT )
LOS ANGELES, July 11, 2025 ( GLOBE NEWSWIRE ) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 11, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. ( "Rocket" or ...
The Gross Law Firm Reminds Rocket Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - RCKT - Rocket Pharmaceuticals ( NASDAQ:RCKT )
NEW YORK, July 10, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. RCKT. Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff ...
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT - Rocket Pharmaceuticals ( NASDAQ:RCKT )
NEW YORK, July 10, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. RCKT between February 27, 2025 and May 26, 2025, both dates inclusive ( the "Class Period" ) , of the important August 11, ...
DEADLINE ALERT for VSTS, RCKT, TEM, and DDD: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - 3D Sys ( NYSE:DDD ) , Rocket Pharmaceuticals ( NASDAQ:RCKT )
LOS ANGELES, July 09, 2025 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Levi & Korsinsky Notifies Shareholders of Rocket Pharmaceuticals, Inc. ( RCKT ) of a Class Action Lawsuit and an Upcoming Deadline - Rocket Pharmaceuticals ( NASDAQ:RCKT )
NEW YORK, July 08, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ( "Rocket" or the "Company" ) RCKT of a class action securities lawsuit.
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - RCKT - Rocket Pharmaceuticals ( NASDAQ:RCKT )
SAN DIEGO, July 08, 2025 ( GLOBE NEWSWIRE ) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before August 11, 2025 to Discuss Your Rights - RCKT - Rocket Pharmaceuticals ( NASDAQ:RCKT )
NEW YORK, July 07, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. RCKT. Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff ...
ROSEN, A LONGSTANDING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT
ROSEN, A LONGSTANDING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action ...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - Rocket Pharmaceuticals ( NASDAQ:RCKT )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options
